non-small cell lung cancer
Conditions
Interventions
treat group :Yiqi Jiedu Tongluo decoction+RGFR-TKI
Sponsors
Shanghai Pulmonary Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. patients with pathologically confirmed NSCLC; 2. patients with stage IIIB-IV; 3. age = 18 years; 4. estimated survival = 3 months; 5. There are no serious diseases such as heart, liver, kidney, and blood system. Laboratory examination before enrollment must meet the following conditions: white blood cell WBC=3.5×10^9/L, hemoglobin Hgb=90g/L, platelet=100×10^9/L, bilirubin=1.5ULN, alkaline phosphatase (AP), Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5ULN, INR = 1.5, creatinine = 1.5ULN; 6. The patient volunteered to participate in the study and signed an informed consent form prior to enrollment.
Exclusion criteria
Exclusion criteria: 1. those with other tumor diseases; 2. those who have received targeted therapy (previously who have undergone surgery, radiotherapy, or chemotherapy, the treatment can be entered 24 weeks after the start of the study); 3. Those with a history of severe cardiovascular disease (including unstable angina, myocardial infarction, congestive heart failure > in NYHA class II); 4. pregnant or lactating patients; 5. people with a history of mental illness that is difficult to control.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| ctDNA;immune indexs;CEA;D-dimer; | — |
Countries
China
Contacts
Public ContactLixin Wang
Shanghai Pulmonary Hospital
Outcome results
None listed